No Data
Actuate to Participate in Lantern's Pharma Webinar on AI-Driven Drug Development
Actuate Therapeutics | 10-Q: Quarterly report
Actuate Announces Scientific Reports Publication on Elraglusib's Novel Immunomodulatory Mechanism of Action as a GSK-3β Inhibitor
Actuate Announces Upcoming Presentation on Initial Data on Elraglusib in Combination With FOLFIRINOX at the AACR Special Conference on Advances in Pancreatic Cancer Research
Alta Copper Announces Non-Brokered Financing With Fortescue Ltd.
Actuate Gets FDA Orphan Designation for Elraglusib in Soft Tissue Sarcomas
No Data
No Data
